CFP
LGND icon

Comprehensive Financial Planning’s Ligand Pharmaceuticals LGND Stock Holding History

Comprehensive Financial Planning’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Hold
66
– – 0.01% 239
2026
Q1 		$13.2K Hold
66
– – 0.01% 247
2025
Q4 		$12.5K Buy
+66
New +$12.7K 0.01% 240

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Comprehensive Financial Planning's LGND Position: Q2 2026 in Review

Comprehensive Financial Planning held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 66 shares worth $20.9K. The position accounts for 0.01% of the portfolio, ranked #239.

Comprehensive Financial Planning first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Comprehensive Financial Planning held 66 shares of Ligand Pharmaceuticals worth $20.9K as of Q2 2026.
  • Comprehensive Financial Planning left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Comprehensive Financial Planning's portfolio in Q2 2026, its #239 holding.
  • Comprehensive Financial Planning first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Comprehensive Financial Planning's 13F filing for Q2 2026, filed 10 Aug 2026.